Lifesci Capital Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Lifesci Capital
Rating: 2.5
Author: MarketBeat

View the latest stock recommendations issued by analysts at Lifesci Capital. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Lifesci Capital's equity research team. MarketBeat is not affiliated with or endorsed by Lifesci Capital.

5 Analysts
Updated 6/16/2026

Brokerage Ranking: Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Total Ratings: 81 Last 12 Months
Buy Ratings: 62 Last 12 Months
Sell Ratings: 0 Last 12 Months
Companies Covered: 68 Last 12 Months

Company	Current Price	Report Date	Analyst	Action	Price Target	Rating	Details
MANE Veradermics	$92.99 +2.2%	6/16/2026	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$135.00	Outperform	View details for Lifesci Capital rating of Veradermics (NYSE:MANE) on 6/16/2026
NUVL Nuvalent	$123.47 +0.1%	6/9/2026		Downgrade	$124.00	Outperform ➝ Hold	View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 6/9/2026
RCUS Arcus Biosciences	$24.20 +2.8%	6/4/2026	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$46.00	Outperform	View details for Lifesci Capital rating of Arcus Biosciences (NYSE:RCUS) on 6/4/2026
ACRS Aclaris Therapeutics	$4.46 +2.6%	6/2/2026		Initiated Coverage	$13.00	Outperform	View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/2/2026
ACRS Aclaris Therapeutics	$4.46 +2.6%	6/1/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/1/2026
KRRO Korro Bio	$11.33 +6.3%	5/29/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Korro Bio (NASDAQ:KRRO) on 5/29/2026
SLGL Sol-Gel Technologies	$71.59 -1.8%	5/15/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Sol-Gel Technologies (NASDAQ:SLGL) on 5/15/2026
MPLT Maplight Therapeutics	$29.07 +7.0%	5/14/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Maplight Therapeutics (NASDAQ:MPLT) on 5/14/2026
IMUX Immunic	$14.41 +5.1%	5/4/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Immunic (NASDAQ:IMUX) on 5/4/2026
STRO Sutro Biopharma	$28.69 +1.8%	5/1/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Sutro Biopharma (NASDAQ:STRO) on 5/1/2026
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
INBX Inhibrx Biosciences	$94.51 +1.5%	4/24/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 4/24/2026
CNTA Centessa Pharmaceuticals	$39.76 +0.0%	4/1/2026		Downgrade		Strong-Buy ➝ Hold	View details for Lifesci Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 4/1/2026
MBX MBX Biosciences	$40.32 +0.6%	3/31/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of MBX Biosciences (NASDAQ:MBX) on 3/31/2026
MREO Mereo BioPharma Group	$0.32 +9.9%	3/19/2026		Upgrade		Hold	View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 3/19/2026
TARS Tarsus Pharmaceuticals	$62.50 +2.8%	3/16/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 3/16/2026
TENX Tenax Therapeutics	$11.69 +3.2%	3/12/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Tenax Therapeutics (NASDAQ:TENX) on 3/12/2026
JBIO Jade Biosciences	$16.44 +5.9%	3/6/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Jade Biosciences (NASDAQ:JBIO) on 3/6/2026
LQDA Liquidia	$67.86 -0.2%	3/5/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 3/5/2026
TNYA Tenaya Therapeutics	$0.72 +5.6%	3/5/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/5/2026
PRME Prime Medicine	$3.19 +11.0%	3/2/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 3/2/2026
RCKT Rocket Pharmaceuticals	$3.17 +13.3%	2/26/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 2/26/2026
SION Sionna Therapeutics	$36.56 +5.2%	2/25/2026	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 2/25/2026
LRMR Larimar Therapeutics	$3.72 +9.3%	2/24/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/24/2026
CNTX Context Therapeutics	$0.61 -6.7%	2/23/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Context Therapeutics (NASDAQ:CNTX) on 2/23/2026
IKT Inhibikase Therapeutics	$1.71 +2.6%	2/23/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 2/23/2026
CRNX Crinetics Pharmaceuticals	$36.09 +3.1%	2/13/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 2/13/2026
CMPS Compass Pathways	$11.94 +3.9%	2/12/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Compass Pathways (NASDAQ:CMPS) on 2/12/2026
IRD Opus Genetics	$4.06 +4.0%	2/12/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Opus Genetics (NASDAQ:IRD) on 2/12/2026
TECX Tectonic Therapeutic	$30.00 0.0%	2/5/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 2/5/2026
DMRA Damora Therapeutics, Inc. Common Stock	$21.16 +2.8%	2/2/2026		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 2/2/2026
NGNE Neurogene	$31.08 +5.9%	1/26/2026	Patrick Dolezal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$50.00	Outperform	View details for Lifesci Capital rating of Neurogene (NASDAQ:NGNE) on 1/26/2026
MREO Mereo BioPharma Group	$0.32 +9.9%	12/29/2025	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Outperform ➝ Hold	View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/29/2025
PRME Prime Medicine	$3.19 +11.0%	12/23/2025		Initiated Coverage	$6.00	Outperform	View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025
PRME Prime Medicine	$3.19 +11.0%	12/23/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025
SION Sionna Therapeutics	$36.56 +5.2%	12/23/2025	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$60.00	Outperform	View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 12/23/2025
OVID Ovid Therapeutics	$2.44 +3.3%	12/22/2025		Initiated Coverage	$4.00	Outperform	View details for Lifesci Capital rating of Ovid Therapeutics (NASDAQ:OVID) on 12/22/2025
IBIO iBio	$1.58 +1.6%	12/18/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of iBio (NASDAQ:IBIO) on 12/18/2025
MAZE Maze Therapeutics	$24.57 +3.0%	12/18/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Maze Therapeutics (NASDAQ:MAZE) on 12/18/2025
EPRX Eupraxia Pharmaceuticals	$6.32 +4.7%	12/11/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 12/11/2025
OCS Oculis	$11.36 -0.8%	12/3/2025		Initiated Coverage	$55.00	Outperform	View details for Lifesci Capital rating of Oculis (NASDAQ:OCS) on 12/3/2025
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free
UPB Upstream Bio	$6.11 +3.2%	12/2/2025		Initiated Coverage	$43.00	Outperform	View details for Lifesci Capital rating of Upstream Bio (NASDAQ:UPB) on 12/2/2025
IKT Inhibikase Therapeutics	$1.71 +2.6%	12/1/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 12/1/2025
ADAG Adagene	$3.50 -0.4%	11/14/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Adagene (NASDAQ:ADAG) on 11/14/2025
KLC KinderCare Learning Companies	$3.85 +1.2%	11/13/2025		Reiterated Rating		Market Perform	View details for Lifesci Capital rating of KinderCare Learning Companies (NYSE:KLC) on 11/13/2025
SRZN Surrozen	$24.89 +9.4%	11/13/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Surrozen (NASDAQ:SRZN) on 11/13/2025
AMLX Amylyx Pharmaceuticals	$15.39 +2.2%	10/27/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/27/2025
KOD Kodiak Sciences	$35.92 +9.0%	10/23/2025	Patrick Dolezal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$40.00	Outperform	View details for Lifesci Capital rating of Kodiak Sciences (NASDAQ:KOD) on 10/23/2025
CADL Candel Therapeutics	$8.13 +2.0%	10/21/2025		Initiated Coverage	$16.00	Outperform	View details for Lifesci Capital rating of Candel Therapeutics (NASDAQ:CADL) on 10/21/2025
DFTX Definium Therapeutics	$24.44 +1.2%	10/14/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Definium Therapeutics (NASDAQ:DFTX) on 10/14/2025
DYN Dyne Therapeutics	$20.00 +10.7%	10/14/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 10/14/2025
SVRA Savara	$5.48 +3.3%	10/14/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Savara (NASDAQ:SVRA) on 10/14/2025
CMPX Compass Therapeutics	$2.10 +6.3%	10/6/2025		Initiated Coverage	$10.00	Outperform	View details for Lifesci Capital rating of Compass Therapeutics (NASDAQ:CMPX) on 10/6/2025
KALA KALA BIO	$2.90 -7.8%	9/29/2025		Downgrade		Strong-Buy ➝ Hold	View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/29/2025
GPCR Structure Therapeutics	$44.59 +3.9%	9/8/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 9/8/2025
AQST Aquestive Therapeutics	$4.40 +3.2%	9/3/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/3/2025
CNTA Centessa Pharmaceuticals	$39.76 +0.0%	9/3/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 9/3/2025
KALA KALA BIO	$2.90 -7.8%	9/3/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/3/2025
PRAX Praxis Precision Medicines	$272.17 +5.8%	9/3/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 9/3/2025
RVMD Revolution Medicines	$159.46 +1.8%	8/18/2025		Initiated Coverage	$80.00	Outperform	View details for Lifesci Capital rating of Revolution Medicines (NASDAQ:RVMD) on 8/18/2025
PVLA Palvella Therapeutics	$113.38 +3.0%	8/4/2025	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$90.00	Outperform	View details for Lifesci Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 8/4/2025
VYNE VYNE Therapeutics	$0.63 -0.1%	7/30/2025		Downgrade		Strong-Buy ➝ Hold	View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 7/30/2025
ABVX Abivax	$102.86 +5.5%	7/23/2025	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$45.00 ➝ $101.00	Outperform	View details for Lifesci Capital rating of Abivax (NASDAQ:ABVX) on 7/23/2025
CATX Perspective Therapeutics	$2.99 +1.9%	7/12/2025	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 7/12/2025
CRBP Corbus Pharmaceuticals	$8.32 +5.6%	7/12/2025		Upgrade		Strong-Buy	View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 7/12/2025
DBVT DBV Technologies	$16.80 +0.3%	6/26/2025	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of DBV Technologies (NASDAQ:DBVT) on 6/26/2025
CBIO Crescent Biopharma	$18.11 +0.9%	6/18/2025	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$22.00	Strong-Buy	View details for Lifesci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 6/18/2025
TECX Tectonic Therapeutic	$30.00 0.0%	6/6/2025		Initiated Coverage	$87.00	Outperform	View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/6/2025
TECX Tectonic Therapeutic	$30.00 0.0%	6/5/2025	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/5/2025
SRRK Scholar Rock	$47.79 +4.9%	6/3/2025	D. Kennedy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Scholar Rock (NASDAQ:SRRK) on 6/3/2025
GLUE Monte Rosa Therapeutics	$18.79 +5.8%	3/12/2025	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$19.00	Outperform	View details for Lifesci Capital rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 3/12/2025
IMNM Immunome	$18.24 +1.8%	3/11/2025	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$20.00	Outperform	View details for Lifesci Capital rating of Immunome (NASDAQ:IMNM) on 3/11/2025
MOLN Molecular Partners	$3.94 +0.6%	3/11/2025	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$12.00	Outperform	View details for Lifesci Capital rating of Molecular Partners (NASDAQ:MOLN) on 3/11/2025
TARA Protara Therapeutics	$4.06 +6.4%	3/11/2025	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$22.00	Outperform	View details for Lifesci Capital rating of Protara Therapeutics (NASDAQ:TARA) on 3/11/2025
ZYME Zymeworks	$23.16 +3.0%	3/11/2025	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$30.00	Outperform	View details for Lifesci Capital rating of Zymeworks (NASDAQ:ZYME) on 3/11/2025
CATX Perspective Therapeutics	$2.99 +1.9%	3/6/2025	D. Kennedy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 3/6/2025
AURA Aura Biosciences	$6.55 +4.3%	1/31/2025	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 1/31/2025
JANX Janux Therapeutics	$14.03 +2.4%	12/27/2024	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Janux Therapeutics (NASDAQ:JANX) on 12/27/2024
MREO Mereo BioPharma Group	$0.32 +9.9%	12/24/2024		Initiated Coverage	$10.00	Outperform	View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/24/2024
MREO Mereo BioPharma Group	$0.32 +9.9%	12/23/2024	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/23/2024
KURA Kura Oncology	$9.48 +0.8%	10/22/2024	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024
OKUR OnKure Therapeutics	$4.45 +4.8%	10/10/2024	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024
LQDA Liquidia	$67.86 -0.2%	10/3/2024		Initiated Coverage	$30.00	Outperform	View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/3/2024
LQDA Liquidia	$67.86 -0.2%	10/2/2024	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/2/2024
ORKA Oruka Therapeutics	$70.03 +3.4%	9/16/2024	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$41.00	Outperform	View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024
AURA Aura Biosciences	$6.55 +4.3%	9/9/2024	A. Dhankher Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024
CELC Celcuity	$87.42 +0.1%	8/26/2024	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$27.00	Outperform	View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024
CRBP Corbus Pharmaceuticals	$8.32 +5.6%	8/21/2024	M. Belghiti Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024
ALXO ALX Oncology	$1.45 +4.7%	7/31/2024	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Strong-Buy ➝ Hold	View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024
IDYA IDEAYA Biosciences	$31.11 +1.8%	7/29/2024	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of IDEAYA Biosciences (NASDAQ:IDYA) on 7/29/2024
NUVL Nuvalent	$123.47 +0.1%	7/29/2024	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 7/29/2024
Trump's New Dollar (Ad) Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. Watch the free briefing and see the three steps to prepare today
DNTH Dianthus Therapeutics	$81.37 +3.2%	6/11/2024	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024
CALT Calliditas Therapeutics AB (publ)	$40.00	5/28/2024	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Strong-Buy ➝ Hold	View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024
CATX Perspective Therapeutics	$2.99 +1.9%	5/6/2024	A. Dhankher Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 5/6/2024
MLYS Mineralys Therapeutics	$25.36 +5.7%	3/26/2024	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024
GPCR Structure Therapeutics	$44.59 +3.9%	2/27/2024	M. Belghiti Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024
LRMR Larimar Therapeutics	$3.72 +9.3%	2/20/2024	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024
INBX Inhibrx Biosciences	$94.51 +1.5%	1/23/2024	Sam Slutsky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Outperform ➝ Market Perform	View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 1/23/2024
IVA Inventiva	$3.54 -1.2%	1/5/2024	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024
RCKT Rocket Pharmaceuticals	$3.17 +13.3%	12/26/2023	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023
TARS Tarsus Pharmaceuticals	$62.50 +2.8%	12/26/2023	Cory Jubinville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Outperform	View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023

MarketBeat Community Rating for Lifesci Capital

MarketBeat's community ratings are surveys of what our community members think about Lifesci Capital and other research firms in the last 90 days. Vote "Outperform" if you believe Lifesci Capital's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Lifesci Capital's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.

COMMUNITY RATINGS: 2.5out of 5 (last 90 days)
2.5 of 5 stars
OUTPERFORM VOTES: 16 Believe will outperform the market
UNDERPERFORM VOTES: 16 Believe will underperform the market

Analysts at Lifesci Capital

Lifesci Capital's equity research team has issued ratings on 68 companies across 3 sectors over the past 12 months, covered by 5 analysts. The Lifesci Capital analysts below are listed by number of ratings issued in the last year.

Lifesci Capital Stock Coverage by Sector

Lifesci Capital concentrates its research most heavily in Medical (89.7%), Manufacturing (8.8%) and Consumer Discretionary (1.5%). The chart below shows how Lifesci Capital's 68 rated companies are distributed across all 3 sectors it covers.

Medical
61 companies
89.7%
Manufacturing
6 companies
8.8%
Consumer Discretionary
1 company
1.5%

Best & Worst Calls

Best Call
0000.0%
NASDAQ:MLTX
Reiterated Rating • Dec 21, 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
OTCMKTS:LHDXQ
Upgrade • Mar 22, 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Similarly Rated Firms

Lifesci Capital - Frequently Asked Questions

Lifesci Capital's analysts currently have buy-equivalent ratings on 57 companies. Recent upgrades to buy include Aclaris Therapeutics, Korro Bio, Sol-Gel Technologies, Maplight Therapeutics and Immunic.

Lifesci Capital has the deepest coverage in Medical (89.7% of rated companies), Manufacturing (8.8% of rated companies) and Consumer Discretionary (1.5% of rated companies).

Lifesci Capital issued 81 ratings over the last 12 months across 68 companies â€” an average of roughly 7 rating actions per month. These include boost price target, downgrade, initiated coverage, reiterated rating and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Lifesci Capital analyst actions.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?